8月1日,四环医药发布盈利预告,预计截至2025年6月30日的六个月收入将不低于11亿元,净利润不低于5000万元。业绩增长主要得益于医美业务持续高增,创新药逐步商业化,仿制药下滑收窄,公司整体财务状况稳健。此前2024年上半年,四环医药营收为9.5亿元,归母净亏损3342.4万元。今年上半年成功实现扭亏为盈,反映出战略布局调整初见成效。截至2025年7月底,集团共获批41个新产品,涵盖医美及医药...
Source Link8月1日,四环医药发布盈利预告,预计截至2025年6月30日的六个月收入将不低于11亿元,净利润不低于5000万元。业绩增长主要得益于医美业务持续高增,创新药逐步商业化,仿制药下滑收窄,公司整体财务状况稳健。此前2024年上半年,四环医药营收为9.5亿元,归母净亏损3342.4万元。今年上半年成功实现扭亏为盈,反映出战略布局调整初见成效。截至2025年7月底,集团共获批41个新产品,涵盖医美及医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.